Author Archives: admin


Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 10, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on March 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 250,300 shares of its common stock to eight new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Continued here:
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 10, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.

Continued here:
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, is aware of reports related to Silicon Valley Bank (“SVB”) and questions raised by interested parties.

More here:
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank

Mersana Therapeutics Provides Statement About SVB

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana’s capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company’s capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB.

Visit link:
Mersana Therapeutics Provides Statement About SVB

Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

LOS ANGELES, March 10, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases, today confirms that neither ImmixBio, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (“SVB”) or Silvergate Bank.

Read the original here:
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates

VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the TSX Venture Exchange (the “TSXV”) to extend the expiry date of 11,414,750 common share purchase warrants (the “Warrants”) issued by the Company. The original term of the Warrants was two years and they currently expire on March 25, 2023. The Company proposes to extend the expiry date by up to 12 months (the “Warrant Extension”). No other terms of the Warrants are to be amended and the exercise price of each Warrant will remain at $0.40. The proposed amendment of the Warrants is subject to TSXV approval. The extension of the Warrants, if any, would only be effective upon TSXV approval and receipt of the requisite confirmation from the holders of the Warrants.

See the rest here:
Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

BOSTON, March 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported that it is aware of the current situation affecting Silicon Valley Bank (SVB), it is monitoring this situation closely and does not expect its exposure to SVB will require any change to its previously provided guidance that it has sufficient cash, cash equivalents and marketable securities to fund operations into 2025.

Read this article:
Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

More than 200 people have been treated with experimental CRISPR … – MIT Technology Review

I watched scientists, ethicists, patient advocacy groups, and others wrestle with these topics at the Third International Summit on Human Genome Editing in London earlier this week.

Theres plenty to get excited about when it comes to gene editing. In the decade since scientists found they could use CRISPR to edit cell genomes, multiple clinical trials have sprung up to test the technologys use for serious diseases. CRISPR has already been used to save some lives and transform others.

But it hasnt all been smooth sailing. Not all of the trials have gone to plan, and some volunteers have died. Successful treatments are likely to be expensive, and thus limited to the wealthy few. And while these trials tend to involve changes to the genes in adult body cells, some are hoping to use CRISPR and other gene-editing tools in eggs, sperm, and embryos. The specter of designer babies continues to loom over the field.

It was at the last summit, held in Hong Kong in 2018, that He Jiankui, then based at the Southern University of Science and Technology in Shenzhen, China, announced that he had used CRISPR on human embryos. The news of the first CRISPR babies, as they became known, caused a massive ruckus, as you might imagine. Well never forget the shock, Victor Dzau, president of the US National Academy of Medicine, told us.

He Jiankui ended up in prison and was released only last year. And while heritable genome editing was already banned in China at the timeit has been outlawed since 2003the country has since enacted a series of additional laws designed to prevent anything like that from happening again. Today, heritable genome editing is prohibited under criminal law, Yaojin Peng of the Beijing Institute of Stem Cell and Regenerative Medicine told the audience.

There was much less drama at this years summit. But there was plenty of emotion. In a session about how gene editing might be used to treat sickle-cell disease, Victoria Gray, a 37-year-old survivor of the disease, took to the stage. She told the audience about how her severe symptoms had disrupted her childhood and adolescence, and scuppered her dreams of training to be a doctor. She described episodes of severe pain that left her hospitalized for months at a time. Her children were worried she might die.

But then she underwent a treatment that involved editing the genes in cells from her bone marrow. Her new super cells, as she calls them, have transformed her life. Within minutes of receiving her transfusion of edited cells, she felt reborn and shed tears of joy, she told us. It took seven to eight months for her to feel better, but after that point, I really began to enjoy the life that I once felt was just passing me by, she said. I could see the typically stoic scientists around me wiping tears from their eyes.

Victoria is one of more than 200 people who have been treated with CRISPR-based therapies in clinical trials, said David Liu of the Broad Institute of MIT and Harvard, who has led the development of new and improved forms of CRISPR. Trials are also underway for a range of other diseases, including cancers, genetic vision loss, and amyloidosis.

Visit link:
More than 200 people have been treated with experimental CRISPR ... - MIT Technology Review

The 30th Biohacking Health and Wellness Biomed EXPO returning to Los Angeles on March 24-26, 2023, latest Stem Cell, Brain enhancement Technologies…

LOS ANGELES, March 7, 2023 /PRNewswire/ -- Biomed Expo ushers in new earth frequencies of biohacking and Trans-Humanism at Sonesta Los Angeles LAX Hotel, on March 24-26. The conference brings together a highly coveted group of physicians to defy the preconceived limits of the human body. With workshops and many exhibitors, this healing fest has curated the leading minds behind the latest leaps in healing modalities from scalar energy to functional homeopathy and Quantum Healing.

Attendees will receive codes on healthcare from a future timeline in which doctors harness Gaia's source codes to help patients of conditions from cancer to Alzheimer's to lupus with non-invasive modalities.

This year's programming will be the largest quantum leap to the future yet: medical researchers, doctors, and disclosure groups, EX- Military Intelligence, California DEPT of Health Whistleblower, and the New Humanity Movement leaders will speak candidly on classified topics including: Tesla's discoveries, Space Science, ET Disclosure, Origin of Man - converging the disciplines of metaphysics and medicine to enhance human cognitive functions, extend lifespan, and expand extrasensory perceptions like clairvoyance.

Keynote speakers:

Dr. Barry Morguelan, M.D., the only western Grand Master of a 5,000-year-old Chinese Source Energy discipline and Founder of Upgrade Labs

Dr. Todd Ovokaitys, M.D. Pioneering Qi-laser resonance technology inventor

Dr. Michael Grossman, M.D. Stem Cell researcher

Dr. Patrick Porter, CEO of BrainTap, Brain Advancement Technologies

Dr. Beverly Rubik, International Biophysicist & EMF Researcher

more amazing speakers:

Dr. Robert Young, The Worldwide Renowned Microbiologist and Virologist.

Dr. Scott Werner, Dr. Jeffrey Benton, Dr. Doug Lehrer, Dr. Vanessa Pavey, Dr. Rollin McCraty, SIR Kaya Redford, Brooks Agnew, Michael Cremo, Dr. Lori Smiskol, Saeed David Farman, Ryan Veli, Ismael Perez, Perry Kamel, Debbie Hawkins, Nichola Burnett, Shehnaz Soni, Veronica Bucheli, Michael Schratt, Azucena Avila, Eric Dadmehr, Robert Potter, Alan Bedian, Michelle Jewsbury, Amelia Brummel, Phillip Wilson, Sandra Biskind, Geraldine Orozco & Julia Galasso.

Story continues

Registration for this three-day extravaganza of meet-and-greet banquet dinners with daily Functional wellness panels and over 100 lectures, workshops on biohacking is now open at https://biomedexpo.com

Cision

View original content:https://www.prnewswire.com/news-releases/the-30th-biohacking-health-and-wellness-biomed-expo-returning-to-los-angeles-on-march-24-26-2023-latest-stem-cell-brain-enhancement-technologies-expo-conference-with-worlds-leading-experts-in-health-longevity-science-consc-301764087.html

SOURCE BIOMED EXPO

View post:
The 30th Biohacking Health and Wellness Biomed EXPO returning to Los Angeles on March 24-26, 2023, latest Stem Cell, Brain enhancement Technologies...